This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Room Temperature Shipping.
Fruzaqla (fruquintinib) is shipped under controlled room temperature conditions (15°C to 25°C) using standard delivery methods to ensure product integrity during transportation.
Disease Indications:
- Colorectal Cancer (Metastatic, previously treated)
Manufacturer:
Takeda Pharma A/S
Usage:
Oral
Fruzaqla (fruquintinib)
General Description:
Fruzaqla (fruquintinib) is a targeted oral therapy prescribed for adults with metastatic colorectal cancer (mCRC) who have previously been treated with chemotherapy, anti-VEGF therapy, and, if suitable, anti-EGFR therapy. Fruzaqla works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), helping to block the growth of blood vessels that supply nutrients to tumors. This inhibition helps slow or stop cancer progression.
Fruzaqla is taken orally once daily, with dosing determined by your oncologist based on your health condition and treatment plan.
Getting Fruzaqla (fruquintinib) in India
Fruzaqla (fruquintinib) has been approved in the United States and China for the treatment of metastatic colorectal cancer. While the medicine is not yet commercially launched in India, it can be legally imported for eligible patients through the Named Patient Program (NPP) under the supervision of a treating physician.
MitoGENE helps Indian patients access Fruzaqla (fruquintinib) safely and compliantly. Our expert team coordinates the documentation, import permissions, and logistics required for import under India’s regulatory framework.
If you or a loved one has advanced or metastatic colorectal cancer, MitoGENE can assist you in obtaining Fruzaqla (fruquintinib) through a secure, patient-centric process.
Medicine Approved by:
- Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Pharmaceuticals and Medical Devices Agency (PMDA)
Available Dosage Form & Package:
- 1 bottle with 21 capsules x 1 mg
- 1 bottle with 21 capsules x 5 mg
How to Access Fruzaqla (fruquintinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Fruzaqla (fruquintinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
